An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis

European Journal of Cancer

Volumn 40, Issue 9, 2004, Pages 1314-1319

  Oude Lashof, A M L ^a   De Bock, R ^b   Herbrecht, R ^c   De Pauw, B E ^a   Krcmery, V ^d   Aoun, M ^e   Akova, M ^f   Cohen, J ^g   Siffnerova H ^h   Egyed, M ⁱ   Ellis, M ^j   Marinus, A ^k   Sylvester, R ^k   Kullberg, B J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d CANCER RESEARCH INSTITUTE   (Slovakia)

^e JULES BORDET INSTITUTE   (Belgium)

^f HACETTEPE UNIVERSITY   (Turkey)

^g HAMMERSMITH HOSPITAL   (United Kingdom)

^h Hospital C Budejovice   (Czech Republic)

ⁱ Department of Obstetrics and Gynecology   (Hungary)

^j UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^k EORTC DATA CENTER   (Belgium)

more..

Author keywords

Cancer patients; Fluconazole; Itraconazole; Multicentre study; Oropharyngeal candidiasis; Treatment

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANDIDIASIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THRUSH; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS, ORAL; FEMALE; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 2942550649     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.03.003     Document Type: Article

References (25)

1. De Wit S., O'Doherty E., De Vroey C., Clumeck N. Safety and efficacy of single-dose fluconazole compared with a 7-day regimen of itraconazole in the treatment of AIDS-related oropharyngeal candidiasis. J. Int. Med. Res. 26:1998;159-170
2. de Repentigny L., Ratelle J. Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. Chemotherapy. 42:1996;374-383
3. Phillips P., Zemcov J., Mahmood W., Montaner J.S., Craib K., Clarke A.M. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. Aids. 10:1996;1369-1376
4. Phillips P., De Beule K., Frechette G., et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin. Infect. Dis. 26:1998;1368-1373
5. Graybill J.R., Vazquez J., Darouiche R.O., et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am. J. Med. 104:1998;33-39
6. Goa K.L., Barradell L.B. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs. 50:1995;658-690
7. Debruyne D., Ryckelynck J.P. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24:1993;10-27
8. Humphrey M.J., Jevons S., Tarbit M.H. Pharmacokinetic evaluation of UK-49, 858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. 28:1985;648-653
9. Koks C.H., Meenhorst P.L., Hillebrand M.J., Bult A., Beijnen J.H. Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob. Agents Chemother. 40:1996;1935-1937
10. Martin M.V. The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. J. Antimicrob. Chemother. 44:1999;429-437
11. Haria M., Bryson H.M., Goa K.L. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 51:1996;585-620
12. Huijgens P.C., Simoons-Smit A.M., van Loenen A.C., et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J. Clin. Pathol. 52:1999;376-380
13. Morgenstern G.R., Prentice A.G., Prentice H.G., Ropner J.E., Schey S.A., Warnock D.W. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br. J. Haematol. 105:1999;901-911
14. Barbaro G., Barbarini G., Calderon W., Grisorio B., Alcini P., Di Lorenzo G. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Candida esophagitis. Gastroenterology. 111:1996;1169-1177
15. Wilcox C.M., Darouiche R.O., Laine L., Moskovitz B.L., Mallegol I., Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J. Infect. Dis. 176:1997;227-232
16. Ruhnke M., Eigler A., Tennagen I., Geiseler B., Engelmann E., Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J. Clin. Microbiol. 32:1994;2092-2098
17. Millon L., Manteaux A., Reboux G., et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J. Clin. Microbiol. 32:1994;1115-1118
18. Johnson E.M., Warnock D.W., Luker J., Porter S.R., Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J. Antimicrob. Chemother. 35:1995;103-114
19. Cameron M.L., Schell W.A., Bruch S., Bartlett J.A., Waskin H.A., Perfect J.R. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 37:1993;2449-2453
20. Goldman M., Cloud G.A., Smedema M., et al. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group. Antimicrob. Agents Chemother. 44:2000;1585-1587
21. Johnson E.M., Davey K.G., Szekely A., Warnock D.W. Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. J. Antimicrob. Chemother. 36:1995;787-793
22. Saag M.S., Fessel W.J., Kaufman C.A., et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res. Hum. Retroviruses. 15:1999;1413-1417
23. Cartledge J.D., Midgley J., Gazzard B.G. Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. Aids. 11:1997;163-168
24. Lim S.G., Sawyerr A.M., Hudson M., Sercombe J., Pounder R.E. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment. Pharmacol. Ther. 7:1993;317-321
25. Zimmermann T., Yeates R.A., Laufen H., Pfaff G., Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur. J. Clin. Pharmacol. 46:1994;147-150